Aveo up on (old) news of Klarman stake
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:00AM CST
OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Ophthotech Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 8:20AM CST
Ophthotech Corporation (NASDAQ: OPHT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
OPHT: 44.93 (+1.06)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Ophthotech Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chairman of the Board and Chief Executive Officer, will present an overview of the Company at the Oppenheimer 25th Annual Healthcare Conference in New York City on Wednesday, December 10, 2014 at 2:45 p.m. ET.
OPHT: 44.93 (+1.06)
InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST
HCOM: 27.34 (+0.27), IPHI: 15.51 (-0.01), JBHT: 84.91 (-0.02), COV: 103.35 (+0.57), OPHT: 44.93 (+1.06), COP: 70.13 (-0.92), SFM: 32.70 (+0.02), GOOG: 528.77 (-1.82), GSAT: 2.97 (+0.03), STAY: 19.60 (-0.31), ZOES: 29.59 (+1.08), INTX: 3.83 (-0.03), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), TRUE: 23.50 (+0.31)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 44.93 (+1.06), REGN: 400.12 (+6.07), NVS: 93.91 (+0.66)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01), AMAG: 43.02 (+0.90)
Ophthotech Corporation to Present at the Stifel 2014 Healthcare Conference
Business Wire - Thu Nov 13, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Stifel 2014 Healthcare Conference in New York City on Tuesday, November 18, 2014 at 8:00 a.m. ET.
OPHT: 44.93 (+1.06)
Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST
OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)
Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 11:12AM CST
OPHT: 44.93 (+1.06)
Ophthotech beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 6:34AM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Tuesday reported net income of $10.9 million in its third quarter.
OPHT: 44.93 (+1.06)
Ophthotech EPS of $0.31
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 5:44AM CST
OPHT: 44.93 (+1.06)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.82 (+0.01), OPHT: 44.93 (+1.06)
Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results
Business Wire - Tue Nov 11, 5:30AM CST
--- Ophthotech Achieves Enrollment Milestone Triggering Third and Final Tranche in Royalty Financing with Novo A/S -
OPHT: 44.93 (+1.06)
Ophthotech Corporation to Present at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2014 Credit Suisse Annual Healthcare Conference in Phoenix, Arizona on Wednesday, November 12, 2014 at 8:00am MST.
OPHT: 44.93 (+1.06)
Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Mon Nov 03, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the third quarter and provide a general business update.
OPHT: 44.93 (+1.06)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 104.59 (+0.31), INSY: 41.52 (+0.51), PTLA: 28.35 (+0.21), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), OPHT: 44.93 (+1.06), IWM: 119.76 (-0.10), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)
Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Business Wire - Fri Oct 03, 6:30AM CDT
--- Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -
OPHT: 44.93 (+1.06)
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 116.03 (-0.18), MRK: 57.46 (+0.25), OPHT: 44.93 (+1.06), TBPH: 14.84 (+0.20)